Chronic Myelomonocytic Leukemia
Oncology·MeSH: Leukemia, Myelomonocytic, Chronic
Prevalence
0.5 / 100K
7 drugs in development·4 companies·14 clinical trials
Drug Pipeline by Phase
Approved(1)
Phase 3(3)
Phase 2(1)
| Drug | Company |
|---|---|
| Ifosfamide | Merus N.V. (MRUS) |
Phase 1(1)
Preclinical(1)
| Drug | Company |
|---|---|
| lenzilumab | HUMANIGEN, INC (HGEN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Chronic Myelomonocytic Leukemia?
BioSniper tracks 7 drugs in development for Chronic Myelomonocytic Leukemia across 4 companies.
How many clinical trials target Chronic Myelomonocytic Leukemia?
There are 14 clinical trials targeting Chronic Myelomonocytic Leukemia tracked by BioSniper.
What is the prevalence of Chronic Myelomonocytic Leukemia?
The estimated prevalence of Chronic Myelomonocytic Leukemia is approximately 0.5 per 100,000 population.
Deep-dive into Chronic Myelomonocytic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis